Autoimmune lymphoproliferative syndrome criteria

Revision as of 04:09, 3 August 2021 by Sharmi Biswas (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Autoimmune lymphoproliferative syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune lymphoproliferative syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune lymphoproliferative syndrome criteria On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome criteria

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune lymphoproliferative syndrome criteria

CDC on Autoimmune lymphoproliferative syndrome criteria

Autoimmune lymphoproliferative syndrome criteria in the news

Blogs on Autoimmune lymphoproliferative syndrome criteria

Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome

Risk calculators and risk factors for Autoimmune lymphoproliferative syndrome criteria

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; David Teachey, MD [2] Associate Editor(s)-in-Chief: Sharmi Biswas, M.B.B.S

Overview

Following the international conference in 2009, a revised set of diagnostic criteria was published in 2010. According to this set of criteria, to reach a definitive diagnosis it is mandatory to have the presence of two required criteria and one primary accessory criteria. The presence of two required criteria and one secondary criterion together indicates the probable diagnosis.

Diagnostic Criteria

Old criteria[1]

  • Required
    • Chronic non-malignant lymphoproliferation
    • Elevated peripheral blood Double Negative T cells (DNTs)
    • Defective in vitro Fas mediated apoptosis

New criteria[2]

  • Required
    • Chronic non-malignant lymphoproliferation (>6 months lymphadenopathy and/or splenomegaly)
    • Elevated peripheral blood DNTs
  • Accessory
    • Primary Accessory
      • Defective in vitro Fas mediated apoptosis
      • Somatic or germline mutation in ALPS causative gene (FAS, FASL, CASP10)
    • Secondary Accessory
      • Elevated biomarkers
        • Plasma sFASL >200pg/ml
        • Plasma IL-10 >20pg/ml
        • Plasma or serum vitamin B12 >1500ng/L
        • Plasma IL-18 >500pg/ml
      • Immunohistochemical findings on biopsy consistent with ALPS as determined by experienced hematopathologist
      • Autoimmune cytopenias and polyclonal hypergammaglobulinemia
      • Family history of ALPS or non-malignant lymphoproliferation
  • Definitive diagnosis: Required plus one primary accessory criteria
  • Probable diagnosis: Required plus one secondary accessory criteria
  • Definitive and Probable ALPS should be TREATED THE SAME and patients counseled that they have ALPS if definitive or probable

References

  1. Sneller MC, Dale JK, Straus SE (2003). "Autoimmune lymphoproliferative syndrome". Curr Opin Rheumatol. 15 (4): 417–21. PMID 12819469.
  2. Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ; et al. (2010). "Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop". Blood. 116 (14): e35–40. doi:10.1182/blood-2010-04-280347. PMC 2953894. PMID 20538792.